Quidel Corp
Cerrado
14.2 -5.4
Resumen
Variación precio
24h
Mínimo
14.09
Máximo
14.43
Ingresos | 39M -92M |
|---|---|
Ventas | -104M 620M |
Margen de beneficios | -14.811 |
Empleados | 6,500 |
Recomendaciones | Vender |
|---|---|
Estimación a 12 Meses | +4.9% upside |
Próximas Ganancias | 4 nov 2026 |
|---|
Capitalización Mercado | 18M 718M |
|---|---|
Apertura anterior | 19.6 |
Cierre anterior | 14.2 |
Quidel Corp Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Quidel Corp previsión
Precio Objetivo
By TipRanks
4.9% repunte
Estimación a 12 Meses
Media 15 USD 4.9%
Máximo 18 USD
Mínimo 12 USD
De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Quidel Corp Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
Beneficio operativo
$
Acerca de Quidel Corp
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
